Marta Gomez-Chiari MD, Presenter: Nothing to Disclose

Alejandro Tomasello MD, Abstract Co-Author: Nothing to Disclose

Antonio Lopez Rueda, Abstract Co-Author: Nothing to Disclose

Jordi Blasco MD, Abstract Co-Author: Nothing to Disclose

Ruben Guerrero Vara MD, Abstract Co-Author: Nothing to Disclose

Juan Miguel Macho, Abstract Co-Author: Nothing to Disclose

Luis San Román, Abstract Co-Author: Nothing to Disclose

Jordi Villalba Aunón MD, Abstract Co-Author: Nothing to Disclose

Flow diverting (FD) devices are self-expanding tight-mesh stents which represents a new tool treatment of wide-neck saccular aneurysms(SA) and fusiform aneurysms (FA)  

We report our treatment experiences with FD during 2010. The patient selection includes unruptured SA with wide-necked (> 4mm), fusiform aneurysms (FA) and repermeabilised of treated aneurysm. All patients received double antiagregation at least 10 days before and 1 month after treatment. We evaluated immediate and late complications and aneurysm thrombosis at 3 months

11 patients and 17 aneurysms were treated (9 women; 50 mean age). 16 aneurysms arose from the ICA and 1 from the vertebrobasilar artery. Mean aneurysm maximum length was 16,5 mm, and mean neck size was 7,8 mm. FD placement was technically successful in 100%, without immediate complications. 23 healthy branches were covered, 4 of these were occluded during the 3 months following up: 2 anterior choroidal and 2 ophthalmic arteries. 15/17 aneurysms presented a complete thrombosis after 3 months, and in an 11, 76 % a low remainder flow was present. 3 of the treated patients had clinical symptoms due to compression and in the follow-up 2 of them had a clinical worsening. One of them recovered completely. Only a significant intrastent stenosis (≥ 70%) was identified. No thromboembolic phenomena, aneurysmatic ruptures or migrations of the implanted FD were detected. (see table)  

FD appears to represent a safe procedure in wide-neck SA and FA treatment. Is important to know certain key points to address the best therapeutic decision. In general longer follow-up and expanded clinical trials are needed to confirm our initial impression

Radiologists should be familiarized with the specific characteristics of the FD in order to know the ideal candidates for this therapeutic option and the potential complications

Gomez-Chiari, M, Tomasello, A, Lopez Rueda, A, Blasco, J, Guerrero Vara, R, Macho, J, San Román, L, Villalba Aunón, J, Our Experience Using Flow-diverting Stents in 17 Aneurysms Treated.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11034292.html